MANNKIND CORP — Board/Management Information 2010

Mar 1, 2010

PAGEBREAK

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 24, 2010

MannKind Corporation

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 000-50865 (Commission File Number) 13-3607736 (IRS Employer Identification No.)

28903 North Avenue Paine Valencia, California (Address of principal executive offices) 91355 (Zip Code)

Registrant’s telephone number, including area code: (661) 775-5300

N/A (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Folio /Folio

PAGEBREAK

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On February 24, 2010, our Board of Directors elected James S. Shannon, M.D., MRCP (UK), as a director effective immediately. Dr. Shannon has not been appointed to any standing committee of our Board of Directors but has been appointed to serve on an ad hoc committee. Dr. Shannon will receive compensation for his service as a director in accordance with our compensation policies for non-employee directors, which are described under “Compensation of Directors” in our proxy statement filed with the Securities and Exchange Commission on April 10, 2009. Dr. Shannon will be offered the opportunity to enter into an indemnity agreement with us in substantially the form filed as an exhibit to our registration statement on Form S-1 (File No. 333-115020), filed with the Securities and Exchange Commission on April 30, 2004, as amended. We are not aware of any transaction with Dr. Shannon requiring disclosure under Item 404(a) of Regulation S-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ David Thomson
Name:	David Thomson, Ph.D., J.D.
Title:	Corporate Vice President, General Counsel
and Secretary

Dated: March 1, 2010

Folio /Folio